ImpriMed - About the company
ImpriMed is a series A company based in Palo Alto (United States), founded in 2017 by Hye Ryeon Lee, Jamin Koo and Sungwon Lim. It operates as a Provider of precision medicines for veterinary cancer. ImpriMed has raised $44.9M in funding from investors like Plug and Play Tech Center, SK Telecom and LB Investment. The company has 9 active competitors, including 5 that are funded. Its top competitors include companies like QBiotics, VetDC and Animal Life Sciences.
Company Details
Provider of precision medicines for veterinary cancer. The company offers different drug combinations suited for a certain cancer pet patient. The company biopsies the live cancer cells for drug responses before treatment. Based on these responses, the company uses its data-driven technology to help veterinary oncologists to fix a personalized medicinal regime for an individual.
- Website
- imprimedicine.com
- Email ID
- *****@imprimedicine.com
- Registered Address
- 4030 Fabian Way Palo Alto, CA 94303
Key Metrics
Founded Year
2017
Location
Palo Alto, United States
Stage
Series A
Total Funding
$44.9M in 6 rounds
Latest Funding Round
Investors
Ranked
1st among 9 active competitors
Employee Count
45 as on Oct 31, 2026
Legal entities associated with ImpriMed
ImpriMed is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Imprimed, Inc. CIN: 82-1496845 , United States, Active | May 03, 2017 | - | 14 (As on Dec 31, 2021) | - |
Sign up to download ImpriMed's company profile
ImpriMed's funding and investors
ImpriMed has raised a total funding of $44.9M over 6 rounds. Its first funding round was on Jun 2018. Its latest funding round was a Series A round on Sep 18, 2026 for $*****. 5 investors participated in its latest round. ImpriMed has 32 institutional investors.
Here is the list of recent funding rounds of ImpriMed:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 18, 2026 | 1090097 | Series A | 3056053 | 9839779 | 4270349 | 5716802 |
Nov 06, 2023 | 4629431 | Series A | 3116218 | 1505488 | 1467460 | |
Apr 13, 2021 | 1654642 | Grant (prize money) | 4151841 | 5491578 | 1944883 | 4104178 |
View details of ImpriMed's funding rounds and investors
ImpriMed's founders and board of directors
Founder? Claim ProfileThe founders of ImpriMed are Hye Ryeon Lee, Jamin Koo and Sungwon Lim. Sungwon Lim is the CEO of ImpriMed.
Here are the details of ImpriMed's key team members:
- Hye Ryeon Lee: Co-Founder of ImpriMed and founder of 1 other company. Contact Info: 1 email address
- Jamin Koo: Co-Founder & CTO of ImpriMed. Contact Info: 1 email address
- Sungwon Lim: Co-Founder & CEO of ImpriMed. Contact Info: 1 email address
View details of ImpriMed's Founder profiles and Board Members
ImpriMed's employee count trend
ImpriMed has 45 employees as of Oct 26. Here is ImpriMed's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ImpriMed's Competitors and alternates
Top competitors of ImpriMed include QBiotics, VetDC and Animal Life Sciences. Here is the list of Top 10 competitors of ImpriMed, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | ImpriMed 2017, Palo Alto (United States), Series A | Provider of precision medicines for veterinary cancer | $44.9M | 49/100 | |
2nd | Developer of small molecules discovered from the plant extracts | $98.1M | 42/100 | ||
3rd | VetDC 2010, Fort Collins (United States), Series A | Developing advanced cancer treatments for pets, enhancing their quality of life | $5.51M | 37/100 | |
4th | Animal Life Sciences 2018, New York City (United States), Seed | Developer of pet food, supplements and therapeutics to treat cancer in animals | $199K | - | 26/100 |
5th | Vetco Pharmaceuticals 2012, Sanchong (Taiwan), Unfunded | Provider of pharmaceutical products for treating cancer in animals | - | - | 24/100 |
6th | CanFel Therapeutics 1999, Torrance (United States), Funding Raised | Developer of therapeutics for treating cancer in animals | - | 23/100 | |
7th | BioTesserae 2022, Corvallis (United States), Seed | Company developing nanobody-based therapies for canine cancer treatment for pet health | $100K | 23/100 | |
8th | Developer of therapeutics for cancer treatment in animals | - | 21/100 | ||
9th | Kyrexa 2023, Edinburgh (United Kingdom), Unfunded | Developer of pharmaceutical treatments for managing cancer in domestic animals | - | - | 16/100 |
10th | Blue Horizon Biotech 2020, United States, Deadpooled | Developer of veterinary therapeutics for the treatment of cancer | - | - | 15/100 |
Looking for more details on ImpriMed's competitors? Click here to see the top ones
ImpriMed's Investments and acquisitions
ImpriMed has made no investments or acquisitions yet.
Reports related to ImpriMed
Here is the latest report on ImpriMed's sector:
News related to ImpriMed
Media has covered ImpriMed for 1 event in last 1 year.
•
NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMedTMC•Sep 18, 2026•Naver, ImpriMed, LB Investment, Samsung Securities and 2 others
•
ImpriMed Accelerates Growth With Strategic Leadership Hire and Major Operational MilestonesBusiness Wire•Oct 14, 2025•ImpriMed
•
•
Imprimed Unveils Groundbreaking Cell-sizing Method For High-accuracy Feline Lymphoma Characterization In Veterinary SciencesBusiness Wire•Aug 12, 2024•ImpriMed
•
•
ImpriMed: Precision Medicine Company Secures $23 Million To Improve Cancer TreatmentPulse 2.0•Dec 21, 2023•ImpriMed, BBVA, HRZ, SK Telecom and 7 others
•
SoftBank Ventures invests in ‘Imprimed’Venture Square•Nov 22, 2023•SoftBank Ventures Asia, ImpriMed, SK Telecom, Korean Development Bank and 5 others
•
SK Telecom invests in enterprise, healthcare AI start-upsTelecompaper•Nov 06, 2023•SK Telecom, Allganize, ImpriMed
•
SKT invests 9.4 billion won in Allganize and ImprimedWowtale•Nov 06, 2023•SK Telecom, Allganize, ImpriMed
•
ImpriMed Raises $8M in Pre-Series A FundingFinSMEs•Apr 15, 2021•ImpriMed, HGI, Draper, Draper Dragon and 7 others
Are you a Founder ?
FAQs about ImpriMed
Explore our recently published companies
- PaddleSmash - United States based, 2021 founded, Unfunded company
- CEP CEC - New Orleans based, Unfunded company
- Utseende - Norway based, Unfunded company
- Caitlin Audrey - Unfunded company
- Wales Bonner - United Kingdom based, 2015 founded, Unfunded company
- EXPIRION - Hillegom based, 2013 founded, Unfunded company